标题
Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors
作者
关键词
-
出版物
Cancers
Volume 12, Issue 4, Pages 1046
出版商
MDPI AG
发表日期
2020-04-24
DOI
10.3390/cancers12041046
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- (2019) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival
- (2019) Petros Christopoulos et al. Cancers
- Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors
- (2019) Léa Berland et al. Journal of Thoracic Disease
- Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
- (2019) S. Schmid et al. LUNG CANCER
- Defining molecular risk in ALK+ NSCLC
- (2019) Petros Christopoulos et al. Oncotarget
- The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?
- (2019) P.H. Patel et al. CLINICAL ONCOLOGY
- Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis
- (2019) Zimu Wang et al. Translational Lung Cancer Research
- LBA79Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials
- (2019) R S Herbst et al. ANNALS OF ONCOLOGY
- LBA80Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
- (2019) L Paz-Ares et al. ANNALS OF ONCOLOGY
- LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042
- (2019) R S Herbst et al. ANNALS OF ONCOLOGY
- LBA5 KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
- (2019) S Gadgeel et al. ANNALS OF ONCOLOGY
- The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma
- (2019) Michele Guida et al. Cancers
- Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer
- (2019) Manon Kissel et al. BMC CANCER
- Reviewing RECIST in the Era of Prolonged and Targeted Therapy
- (2018) Rustain L. Morgan et al. Journal of Thoracic Oncology
- Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors
- (2018) Ioannis Gkiozos et al. Journal of Thoracic Oncology
- Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance
- (2018) Petros Christopoulos et al. LUNG CANCER
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients
- (2018) Michael T. Tetzlaff et al. Journal for ImmunoTherapy of Cancer
- Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
- (2018) Sabine Schmid et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
- (2018) D. Ross Camidge et al. NEW ENGLAND JOURNAL OF MEDICINE
- The current state of oligometastatic and oligoprogressive non-small cell lung cancer
- (2018) Vasu Tumati et al. Journal of Thoracic Disease
- 10PClinical and laboratory predictors of immune checkpoint inhibitor efficacy in non-small cell lung cancer
- (2018) P Christopoulos et al. ANNALS OF ONCOLOGY
- P3.02c-033 Patterns of Progression and Management of Acquired Resistance to Anti-PD-1 Antibodies in Advanced Non-Small Cell Lung Cancer
- (2017) Antony Mersiades et al. Journal of Thoracic Oncology
- Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non–Small Cell Lung Cancer
- (2017) Chul Kim et al. Journal of Thoracic Oncology
- The immune contexture in cancer prognosis and treatment
- (2017) Wolf H. Fridman et al. Nature Reviews Clinical Oncology
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
- (2017) Paul C. Tumeh et al. Cancer Immunology Research
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- Prognostic effect of liver metastasis in lung cancer patients with distant metastasis
- (2016) Yijiu Ren et al. Oncotarget
- An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer
- (2014) Allison B. Ashworth et al. Clinical Lung Cancer
- Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib
- (2014) Gregory N. Gan et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
- (2013) Helena A. Yu et al. Journal of Thoracic Oncology
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer
- (2012) Andrew J. Weickhardt et al. Journal of Thoracic Oncology
- Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure
- (2011) Takehito Shukuya et al. LUNG CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More